Betmiga generics’ market share rises to 49%...
By Kim, Jin-Gu | translator Kim, Jung-Ju
23.05.06 05:50:55
가나다라
0
Mirabek KRW 3.8 billion, Selebeta KRW 1.7 billion.... original drug’s sales drop to half in 3 years
Jeil’s Beova and Dong-A’s DA-8010 to soon be released...remains a variable in Korea’s OAD market
▲Miragegron original Betmiga (left) and its generic versions Mirabek and Selebeta (right)
Generic versions of mirabegron have increased their influence in Korea’s overactive bladder market.The overall market share of the generic products in Q1 was 49%, chasing sales of the original drug, ‘Betmiga,’ right under the nose. In particular, sales of Hanmi Pharmaceuticals ‘Mirabek’ and Chong Kun Dang’s ‘Selebeta’ have shown rapid growth.
On the other hand, the prescription performance of the original product, Astellas Betmiga, dropped to less than half in 3 years after the release of its generics.
Betmiga’s generics increase market share to 49%...Sales of original continue to decline
According to the market research institution UBSIT on
Kim, Jin-Gu(kjg@dailypharm.com)
If you want to see the full article, please JOIN US (click)